Introduction {#Sec1}
============

Endometrial cells are constantly under the oxidative stress during menstrual cycles \[[@CR1]\]. The stress is generated in the metabolic reactions of estrogens, producing reactive oxygen species (ROS), which can cause damages to biomolecules, including DNA \[[@CR2]\]. ROS may induce mutations in proto-oncogenes and tumor suppressor genes, as well as in other genes important for induction, promotion and progression of cancer, accelerating up malignant transformation \[[@CR3], [@CR4]\]. Oxidative damages to the DNA bases are mainly removed by base excision repair (BER) pathway. hOGG1 is a key BER enzyme to recognize and excise of 8-hydroxy-deoxyguanine (8-oxo-dG), which cause G\>A transversion \[[@CR5]--[@CR8]\].

*hOGG1*, the gene encoding hOGG1, is highly polymorphic \[[@CR9]\]. A C\>G transversion at the 1245 position in the exon 7 of the gene results in a serine to cysteine substitution in the codon 326 (the Ser326Cys polymorphism; rs 1052133). The role of this polymorphism in the catalytic activity of the hOGG1 protein is still controversial. Several studies have suggested that Cys326 allele may be associated with the increased risk cancers \[[@CR10]--[@CR21]\]. For prostate cancer it was shown that Cys326Cys variant of hOGG1 reduced cancer risk of more aggressive disease \[[@CR22]\].

Hydroxyl radicals can attack sugar-phosphate backbone of DNA, producing single strand breaks, which could be converted into double strand breaks (DSBs) in replication or generation of another single strand break on the opposite DNA strand. RAD51-depended homologous DNA recombination repair (HRR) is one of major pathways for the repair of DSBs in human cells. HRR has been implicated in the resuming of stalled replication fork and RAD51 protein plays essential role in this process. HRR is also involved in the repair of DNA-protein cross-links in cooperation with nucleotide excision repair (NER). Human RAD51 is required for meiotic and mitotic recombination and plays a central role in homology-dependent recombinational repair of DSBs \[[@CR23], [@CR24]\]. A single nucleotide polymorphism in the 5′-untranslated region (5′-UTR) of the human *RAD51* gene, resulting in a G\>C substitution at the 135 position (the 135G\>C polymorphism; c. −98 G\>C; rs 1801320), has been identified \[[@CR25]\]. We showed previously that this polymorphism was not an independent marker in breast cancer, but it could be associated with an increased gastric cancer risk and an increased breast cancer risk in *BRCA2* mutation carriers \[[@CR26], [@CR27]\]. Similar results came from other laboratories \[[@CR25], [@CR28]\].

In the present work we tried to correlate the genetic constitution expressed by genotypes of the Ser326Cys and 135G\>C polymorphisms of the *hOGG1* and *RAD51* genes, respectively, with susceptibility to DNA damage and efficacy of DNA repair in human lymphocytes of endometrial cancer patients. To evaluate the extent of DNA damage, the effectiveness of DNA repair and the sensitivity to exogenous mutagens we determined: (1) the level of basal DNA damage and (2) the capacity to remove DNA damage induced by hydrogen peroxide and N-methyl-N′-nitro N-nitrosoguanidyne (MNNG) in peripheral blood lymphocytes of endometrial cancer patients and healthy individuals. DNA damage and repair were evaluated by alkaline single cell gel electrophoresis (comet assay).

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

Blood samples were obtained from 30 patients with histologically confirmed endometrial cancer (median age 55 years) treated at the Department of Oncological Surgery, N. Copernicus Hospital (Lodz, Poland) and Polish Mother's Memorial Hospital (Lodz, Poland) in 2006 and 2007 and 30 cancer-free age-matched women. Blood from patients was collected before surgical treatment and radiotherapy. The study was approved by the Local Ethic Committee and each patient gave a written consent.

Cell preparation {#Sec4}
----------------

Blood samples were immediately transported to the laboratory on ice. Peripheral blood lymphocytes (PBL) were isolated by centrifugation in a density gradient of Histopaque-1077 (15 min, 280 × *g*). The pellet containing PBL was resuspended in RPMI 1640 medium to give about (1--3) × 10^5^ cells per ml and further processed.

Comet assay {#Sec5}
-----------

The comet assay was performed under alkaline conditions essentially according to the procedure of Singh et al. \[[@CR29]\] with some modifications as described previously \[[@CR30]\].

Peripheral blood lymphocytes were incubated with hydrogen peroxide (10 mM for 10 min at 0°C) and MNNG (200 nM for 1 h at 37°C) to evaluate the efficacy of DNA repair. After incubation, cells were washed and incubated in a fresh, drug-free medium for 2 h at 37°C. The comets were observed at ×200 magnification in an Eclipse fluorescence microscope (Nikon, Tokyo, Japan) attached to a COHU 4910 video camera (Cohu, San Diego, CA, USA) equipped with UV-1 filter block (an excitation filter of 359 nm and a barrier filter of 461 nm) and connected to a personal computer-based Lucia-Comet v. 4.51 image analysis system (Laboratory Imaging, Prague, Czech Republic). The mean of percentage of DNA in the tail of comet for a total of 100 cells was calculated. All the values in this study were expressed as mean ± SE.

Genotype determination {#Sec6}
----------------------

Genomic DNA was prepared by the standard phenol procedure as we described previously \[[@CR31]\]. *RAD51* genotyping was analyzed by a PCR amplification of a 157-bp region around the 135th nucleotide. This region contains a single *Mva*I site that was abolished in the 135C variant. Wild type alleles were digested by *Mva*I (Fermentas, Vilnius, Lithuania) producing 86 and 71 bp length products. The 135C variant of *RAD51* was not digested by the enzyme, giving a single 157 bp PCR product. PCR was performed in a MT Research, INC thermal cycler with the following primers: sense: 5′-TGGGAACTGCAACTCATCTGG-3′ and 5′-GCGCTCCTCTCTCCAGCAG-3′ at a final Mg^2+^ concentration of 1.5 mM and annealing temperature of 53°C. After overnight digestion with the enzyme, the samples were separated onto a 8% polyacrylamide gel. The genotypes of the other polymorphism were determined with the following primers: sense 5′-GTTTTCACTAATGAGCTTGC-3′, antisense 5′-AGTGGTATAATCATGTGGGT-3′ at a final Mg^2+^ concentration of 1.5 mM and annealing temperature of 57°C. The 200 bp PCR product was digested overnight with 5 U of the restriction enzyme *Sat*I (Fermentas, Vilnius, Lithuania). The Cys allele was digested into 100 bp fragments whereas the Ser variant remained intact. The PCR products were run on a 8% of polyacrylamide gel \[[@CR12], [@CR26], [@CR27]\].

Data analysis {#Sec7}
-------------

Distribution of genotypes and alleles between groups were analyzed using the *χ*2-test. Relationship between genotype and cancer was assessed by the unconditional logistic regression (quasi-Newton method). For each SNP, odds ratio (OR) was estimated. Wild type alleles or additional homozygous variants were used as reference groups. Efficacy of DNA repair was analyzed using Wilcoxon matched pair test. Analyses were performed using STATISTICA 8.0 package (Statsoft, Tulusa, OK, USA) and *P* \< 0.05 was considered statistically significant.

Results {#Sec8}
=======

DNA damage {#Sec9}
----------

The mean extent of endogenous DNA damage measured as the percentage of DNA in comet tail of the lymphocytes of endometrial cancer patients and controls is displayed in Fig. [1](#Fig1){ref-type="fig"}. There were no differences between the extents of DNA damage for both groups (*P* \> 0.05).Fig. 1Endogenous DNA damage (DNA strand breaks and alkali labile sites), measured as the mean percentage of comet tail DNA in the alkaline comet assay in human peripheral blood lymphocytes of healthy controls and endometrial cancer patients. Thirty individuals were analyzed in either group. The results displayed are the mean ± SE

Sensitivity to DNA-damaging agents and efficacy of DNA repair {#Sec10}
-------------------------------------------------------------

The mean percentage tail DNA of PBL from endometrial cancer patients and controls exposed to 10 mM hydrogen peroxide or 200 nM MNNG immediately after the exposure as well as 120 min thereafter are presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. We do not observed any differences in the mean sensitivity to hydrogen peroxide and MNNG (the mean extent of DNA damage immediately after exposure) for patients and controls. We observed a great variation in the individual efficacy of DNA repair. Both patients and controls had comparable number of subjects with inefficient DNA repair, in other words, with not any statistically significant difference between the level of DNA damage at 120 and 0 min (bolded).Table 1Repair of hydrogen peroxide-induced DNA damage in 30 endometrial cancer patients and 30 healthy controlsEndometrial cancer DNA damage ± SEControl DNA damage ± SENumber0 min120 min*P*Number0 min120 min*P*116.5 ± 5.555.33 ± 0.79\<0.05117.3 ± 0.667.52 ± 0.91\<0.0529.44 ± 3.053.23 ± 0.44\<0.05215.7 ± 3.202.61 ± 0.81\<0.0538.43 ± 2.460.87 ± 1.12\<0.0539.59 ± 1.881.57 ± 0.87\<0.05412.5 ± 3.326.04 ± 1.61\<0.05419.8 ± 0.589.76 ± 2.03\<0.0557.99 ± 2.704.95 ± 1.17\<0.05514.8 ± 0.1110.3 ± 0.52\<0.0567.68 ± 1.614.48 ± 2.12\<0.05658.1 ± 3.3912.3 ± 3.02\<0.05**722.6** ± **1.4423.9** ± **1.720.2567**746.7 ± 3.366.49 ± 0.63\<0.05**859.0** ± **12.7448.3** ± **5.460.2972829.9** ± **1.4826.6** ± **2.120.2972**914.5 ± 1.177.06 ± 1.98\<0.05920.5 ± 2.0010.8 ± 0.62\<0.051018.6 ± 3.1511.3 ± 1.48\<0.051076.5 ± 3.618.77 ± 2.40\<0.051116.4 ± 2.588.43 ± 0.84\<0.0511**22.9** ± **0.5924.0** ± **2.030.4314**1225.3 ± 2.268.13 ± 1.75\<0.051222.6 ± 2.243.92 ± 0.38\<0.051325.7 ± 1.086.06 ± 2.46\<0.051318.2 ± 1.481.61 ± 0.45\<0.05**1467.5** ± **2.8759.6** ± **2.550.2894**148.33 ± 0.983.77 ± 1.72\<0.051539.0 ± 2.4525.0 ± 2.81\<0.051529.0 ± 2.321.17 ± 0.63\<0.051628.9 ± 2.3919.0 ± 1.20\<0.05**1610.4** ± **1.529.19** ± **1.730.2540**1747.3 ± 5.3335.1 ± 2.78\<0.05179.8 ± 5.096.84 ± 1.72\<0.051826.6 ± 3.017.41 ± 0.84\<0.0518**28.3** ± **3.6122.7** ± **3.960.44861914.5** ± **3.2711.8** ± **4.030.0814**1922.2 ± 1.9414.5 ± 1.52\<0.05**2012.0** ± **2.0313.8** ± **2.010.0978**2027.8 ± 1.2913.7 ± 1.85\<0.052119.1 ± 3.646.23 ± 1.36\<0.052125.0 ± 3.1412.6 ± 2.16\<0.052221.7 ± 3.643.66 ± 2.11\<0.052228.5 ± 3.982.87 ± 2.85\<0.052313.5 ± 3.267.94 ± 2.28\<0.052318.0 ± 1.113.35 ± 0.86\<0.052417.3 ± 1.147.52 ± 1.19\<0.052418.8 ± 2.2211.3 ± 3.09\<0.05**2511.4** ± **1.0611.4** ± **1.480.8281257.19** ± **1.617.69** ± **1.800.1080**2615.7 ± 1.123.77 ± 1.35\<0.052658.9 ± 3.078.78 ± 1.03\<0.052724.5 ± 2.6711.9 ± 2.38\<0.0527**10.7** ± **1.9410.5** ± **1.140.2994**2823.8 ± 1.888.22 ± 1.51\<0.0528**24.5** ± **2.0727.3** ± **1.480.2103**29**10.7** ± **1.4410.5** ± **1.010.0767**2911.2 ± 1.178.05 ± 0.77\<0.053022.1 ± 1.696.75 ± 1.64\<0.053011.9 ± 1.225.89 ± 0.88\<0.05DNA damage for each treatment was analyzed as the percentage of DNA in the tail of 100 comets; mean ± SE. The efficacy of DNA repair was calculated by comparing the extent of DNA damage immediately and 120 min after hydrogen peroxide treatment using Wilcoxon matched pairs test. The subjects with no significant repair (*P* \> 0.05) are presented *bold*Table 2Repair of MNNG-induced DNA damage in 30 endometrial cancer patients and 30 healthy controlsEndometrial cancer DNA damage ± SEControl DNA damage ± SENumber0 min120 min*P*Number0 min120 min*P*124.2 ± 3.0913.3 ± 0.56\<0.05115.2 ± 2.825.35 ± 0.30\<0.05210.2 ± 0.683.93 ± 1.16\<0.05215.4 ± 0.673.99 ± 0.62\<0.0535.94 ± 1.832.41 ± 0.25\<0.05317.0 ± 1.946.16 ± 0.50\<0.054**9.94** ± **0.755.55** ± **2.320.069**412.7 ± 1.547.36 ± 1.80\<0.05516.8 ± 1.422.61 ± 0.34\<0.05514.9 ± 0.735.22 ± 2.12\<0.0565.46 ± 0.713.02 ± 1.20\<0.05646.3 ± 2.0221.7 ± 1.08\<0.05736.8 ± 3.711.4 ± 0.86\<0.05731.3 ± 0.5713.5 ± 1.27\<0.058**37.4** ± **2.2537.0** ± **0.580.760**8**36.5** ± **2.1536.0** ± **1.540.942**915.3 ± 2.007.56 ± 0.46\<0.059**21.3** ± **1.0928.1** ± **3.95--**109.85 ± 0.735.25 ± 0.55\<0.051095.9 ± 1.7414.5 ± 0.82\<0.0511**9.44** ± **1.407.57** ± **2.430.083**11**26.3** ± **1.7225.6** ± **2.030.853**1221.3 ± 2.258.56 ± 0.63\<0.051236.8 ± 3.8111.4 ± 0.89\<0.051327.5 ± 0.318.81 ± 0.39\<0.051310.6 ± 0.676.51 ± 1.22\<0.0514**70.0** ± **0.7454.5** ± **2.900.058**1410.5 ± 0.793.69 ± 0.98\<0.051517.0 ± 0.479.54 ± 0.30\<0.051513.7 ± 1.191.41 ± 0.14\<0.0516**20.7** ± **0.3925.8** ± **2.260.067**16**5.68** ± **3.955.53** ± **1.750.546**1745.2 ± 0.2921.5 ± 0.28\<0.05176.52 ± 0.842.23 ± 3.74\<0.051839.0 ± 0.517.27 ± 0.21\<0.0518**12.5** ± **2.0314.4** ± **1.310.070**19**10.5** ± **1.659.44** ± **1.350.453**1933.2 ± 0.7814.6 ± 0.60\<0.0520**10.5** ± **2.8914.1** ± **2.040.098**2024.3 ± 1.7515.9 ± 1.53\<0.05219.14 ± 2.014.23 ± 0.84\<0.052132.5 ± 1.3316.1 ± 0.99\<0.052213.3 ± 1.274.77 ± 0.83\<0.052216.9 ± 1.106.69 ± 1.34\<0.05238.30 ± 3.232.77 ± 0.59\<0.0523**14.9** ± **2.1912.8** ± **0.860.084**2415.2 ± 2.425.35 ± 0.45\<0.052419.9 ± 0.402.64 ± 1.97\<0.05259.09 ± 1.364.26 ± 0.84\<0.05257.64 ± 0.663.2 ± 2.07\<0.052615.7 ± 0.663.99 ± 0.66\<0.052652.7 ± 1.9511.4 ± 2.23\<0.052715.5 ± 2.285.79 ± 1.09\<0.05277.64 ± 0.463.20 ± 0.07\<0.052829.4 ± 1.2219.9 ± 2.58\<0.0528**15.5** ± **3.8114.0** ± **2.350.750**2917.2 ± 0.7311.7 ± 1.74\<0.052912.3 ± 0.646.06 ± 0.52\<0.053011.0 ± 0.356.56 ± 0.45\<0.053011.9 ± 0.924.48 ± 0.53\<0.05"--" Not estimatedDNA damage for each treatment was analyzed as the percentage of DNA in the tail of 100 comets; mean ± SE. The efficacy of DNA repair was calculated by comparing the extent of DNA damage immediately and 120 min after MNNG treatment using Wilcoxon matched pairs test. The subjects with no significant repair (*P* \> 0.05) are presented *bold*

Genotype analysis {#Sec11}
-----------------

Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} show the distribution of genotypes of the Ser326Cys and 135G\>C polymorphism for cancer patients and controls. A strong association of the C/C genotype (OR 25.3, 95% CI 4.48--143) and the C allele (OR 7.23, 95% CI 3.20--16.35) and endometrial cancer occurrence was observed. Table [5](#Tab5){ref-type="table"} shows the distribution of genotypes of the 135G\>C polymorphism in patients and controls with high, i.e. higher than median, level of endogenous DNA damage. There was a strong association between endometrial cancer occurrence and the C/C genotype (OR 13.2, 95% CI 1.47--123) and the C allele (OR 4.75, 95% CI 1.58--14.3) in patients with elevated level of basal DNA lesions. There were no significant differences between the distributions of the other polymorphism in cancer patients and controls with high level of endogenous DNA damage (Table [6](#Tab6){ref-type="table"}). No correlation was found between both polymorphism and endometrial cancer occurrence in subjects with impaired DNA repair after hydrogen peroxide and MNNG treatment (data not shown).Table 3The allele and genotype frequencies and odds ratio (OR) of the Ser326Cys polymorphism of the *OGG1* gene in endometrial cancer patients and non-cancer patientsGenotype or allelePatients (*n* = 30)Controls (*n* = 30)OR (95% CI)NumberNumberSer/Ser23221.00 ref.Ser/Cys670.82 (0.24--2.83)Cys/Cys110.96 (0.06--16.3)Ser52511.00 ref.Cys890.87 (0.31--2.44)χ^2^ = 0.319031, *P* \< 0.9886Table 4The allele and genotype frequencies and odds ratio (OR) of the 135G\>C polymorphism of the *RAD51* gene in endometrial cancer patients and non-cancer patientsGenotype or allelePatients (*n* = 30)Controls (*n* = 30)OR (95% CI)NumberNumberGG6191.00 ref.GC892.81 (0.75--10.6)CC162**25.3** (**4.48**--**143**)G20471.00 ref.C40137.23 (3.20--16.4)χ^2^ = 178.5934, *P* \< 0.0001Table 5The allele and genotype frequencies and odds ratio (OR) of the Ser326Cys polymorphism of the *OGG1* gene in endometrial cancer patients and non-cancer patients with high level of endogenous DNA damageGenotype or allelePatients (*n* = 15)Controls (*n* = 15)OR (95% CI)NumberNumberSer/Ser10101.00 ref.Ser/Cys450.80 (0.16--3.88)Cys/Cys10--Ser24251.00 ref.Cys651.25 (0.34--4.64)"--" Not estimated; χ^2^ = 0.4400, *P* \< 0.9791Table 6The allele and genotype frequencies and odds ratio (OR) of the 135G\>C polymorphism of the *RAD51* gene in endometrial cancer patients and non-cancer patients with high level of endogenous DNA damageGenotype or allelePatients (*n* = 15)Controls (*n* = 15)OR (95% CI)NumberNumberGG261.00 ref.GC471.71 (0.23--12.9)CC92**13.2** (**1.47**--**123**)G8191.00 ref.C22114.75 (1.58--14.3)χ^2^ = 45.8208, *P* \< 0.0001

Discussion {#Sec12}
==========

In our study we did not observe any difference between basal endogenous level of DNA damage in lymphocytes of endometrial cancer patients and non-cancer controls. The same concerns the susceptibility of lymphocytes to DNA-damaging agent in these two groups. On the other hand, it was shown that a long-term estrogens exposure was associated with endometrial and ovarian cancer risk \[[@CR32]\]. Estrogen metabolites can cause DNA damage in many tissues \[[@CR33], [@CR34]\]. Primarily they form unstable N-3 adenine and N-7 guanine adducts resulting in mutagenic apurinic sites, witch are easily detected by comet assay. The alkaline single cell-gel electrophoresis was used to examine oestrogens (beta-estradiol, estrone and estriol) activities on the estrogen-responsive MCF-7 human breast cancer cells for chromosomal damage and DNA single-strand breaks (SSBs). Both beta-estradiol and estrone induced dose-related increases in SSBs (up to sevenfold over control) at concentrations as low as 10^−9^ and 10^−8^ M, while estriol was less genotoxic \[[@CR35]\]. In the present study we showed that genotoxic effect of estrogens cannot be observed in non estrogen-responsive target cells, such as lymphocytes. We showed that there are no significant differences in basal endogenous DNA damage in lymphocytes from patients with endometrial cancer and healthy controls. It is in agreement with other studies performed on human lymphocytes \[[@CR36]--[@CR38]\].

Our results obtained for the 135G\>C polymorphism of the *RAD51* gene indicated that both the C/C genotype and the C allele are strongly associated with endometrial cancer. The 135G\>C polymorphism of the *RAD51* gene was reported to change breast cancer risk in *BRCA2* mutations carriers \[[@CR25], [@CR26], [@CR28]\]. It is located in the 5′-untranslated region of the *RAD51* gene, so it could affect the gene expression and, as a consequence, alter the concentration of the final product---the RAD51 protein. RAD51 takes a part in the repair of DNA double strand breaks (DSBs), the most dangerous damage to DNA. The formation of RAD51 foci represents an important step in the repair of DNA double-strand breaks. RAD51 foci also appear during S phase and are thought to be required for the restart of stalled or broken replication fork. The RAD51 recombinase interacts directly with the breast cancer-associated tumor suppressor BRCA2 and this interaction is required for normal recombination proficiency, radiation resistance and genome stability \[[@CR39]--[@CR46]\]. There are no epidemiological studies linked the 135G\>C polymorphism with endometrial cancer. Studies in mice suggested a role of polymorphic variants of *RAD51* in radiation induced acute myeloid leukemia \[[@CR47]\].

Antoniou et al. suggests an effect of the *RAD51* 135C homozygotes on the *RAD51* alternative splicing within the 5′ UTR. Isoform for 135C genotype has lower translation efficiency and may cause an overall lower abundance of RAD51 protein \[[@CR48]\].

Our present data confirm our previous suggestion that the 135G\>C polymorphism of the *RAD51* gene have a phenotypic effect, manifested in the changes in the extent of DNA damage \[[@CR12]\].

Human tumors often display loss of heterozygosity at the *hOGG1* locus. Bacterial and yeast cells deficient in the repair of 8-oxoG repair display a hypermutator phenotype \[[@CR49], [@CR50]\]. Mice deficient for *ogg1* accumulate abnormal levels of 8-oxoG and have an elevated spontaneous mutation rate \[[@CR51]\]. It was suggested that hOGG1--Cys326 enzyme had a lover ability to suppress mutation than wild type Ser326 protein in human cells in vitro \[[@CR52]\]. Even though no differences in catalytic activity was shown among Ser326 and Cys326 variants in one study \[[@CR36]\], the other shows that Ser326Cys and Cys326Cys genotypes displayed slower DNA repair than the Ser326Ser genotype \[[@CR53]\] and the hOGG1 protein encoded by the Ser326 allele had significantly higher activity than the Cys326 variants in an in vitro complementation activities assay \[[@CR6]\]. Interestingly, this effect is not related to difference in the expression rate of polymorphic variants. The hOGG1 Cys326Cys genotype had significantly higher expression level of the hOGG1 mRNA than Ser326Ser genotype \[[@CR54], [@CR55]\]. Replacement of wild type serine at residue 326 (allele frequencies of 0.55--0.67 in Asians and 0.73--0.78 in the Caucasians populations) with redox sensitive cysteine resulted in attenuated activity under oxidative stress. It is also possible that loss of phosphorylation site on Ser326 provide to aberrant nuclear localization of the Cys variant of the enzyme \[[@CR56], [@CR57]\].

In summary, our results suggest that the variants of the 135G\>C polymorphism of the *RAD51* gene can be associated with the occurrence of endometrial cancer in individuals with a high level of DNA damage. Therefore, this polymorphism can be considered as an additional marker in endometrial cancer.
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